Spots Global Cancer Trial Database for Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Official Title: A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

Study ID: NCT05034497

Conditions

Leptomeningeal Metastasis

Interventions

186RNL

Study Description

Brief Summary: This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).

Detailed Description: This Phase I clinical study evaluates a single dose of 186RNL (radionuclide clinical study drug) administered through an intraventricular catheter (Ommaya reservoir) in participants with Leptomeningeal Metastases (LM). The clinical study treatment consists of a single administered 5cc dose of 186RNL per participant. The clinical study will include the evaluation at separate dose levels. Three to six participants may be treated at each dose. The maximum number of participants to be enrolled in the study is 27. The clinical study treatment will be administered, following a CSF flow study, on an outpatient basis by the clinical study physician. Participants will be followed for up to 12 months after the clinical study drug is administered. The U.S. Food and Drug Administration (FDA) has not approved 186RNL for this specific disease.